Mazaticol

Mazaticol
Clinical data
Routes of; administration	Oral
ATC code	N04AA10 (WHO) ;
Legal status
Legal status	In general: uncontrolled;
Identifiers
	IUPAC name [(1R,3R,5R)-6,6,9-trimethyl-9-azabicyclo[3.3.1]non-3-yl hydroxy(di-2-thienyl)acetate;
CAS Number	42024-98-6;
PubChem CID	68667;
ChemSpider	61921;
UNII	I6X824OGWZ;
CompTox Dashboard (EPA)	DTXSID1057743 ;
Chemical and physical data
Formula	C21H27NO3S2
Molar mass	405.57 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1(CC[C@@H]2C[C@H](C[C@H]1N2C)OC(=O)C(c3cccs3)(c4cccs4)O)C;
	InChI InChI=1S/C21H27NO3S2/c1-20(2)9-8-14-12-15(13-16(20)22(14)3)25-19(23)21(24,17-6-4-10-26-17)18-7-5-11-27-18/h4-7,10-11,14-16,24H,8-9,12-13H2,1-3H3/t14-,15-,16-/m1/s1; Key:AMHPTVWBZSYFSS-BZUAXINKSA-N;
	(verify)

Mazaticol (Pentona) is an anticholinergic used as an antiparkinsonian agent in Japan.

The compound was known as PG-501 is first mentioned in Japanese studies in the early 1970s, noting "PG-501 was found to have pronounced anti-acetylcholine, anti-tremorine-induced tremor, anti-physostigmine-induced death, anti-haloperidol-induced parkinsonism and anti EEG arousal activities."^[1]^[2]

References

^ Nose T, Kojima M, Ishida R, Shintomi K, Kowa Y (July 1971). "[Pharmacological properties of 6,6,9-trimethyl-9-azabicyclo (3,3,1)non-3 beta-yl-alpha, alpha-di(2-thienyl) glycolate hydrochloride monohydrate (PG-501), a new anti-parkinsonian agent]". Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica (in Japanese). 67 (4): 387–405. doi:10.1254/fpj.67.387. PMID 5000167.
^ Kosaka K (1971). "パーキンソン病に対するPG-501の使用経験/The Beneficial Effect of PG-501 on Parkinsonism". Rinsho Yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics. 2 (3): 230–235. doi:10.3999/jscpt.2.230. Retrieved December 18, 2023.

External links

Government registered description of mazaticol (Pentona) (Japanese)^{[permanent dead link]}

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

[1] Nose T, Kojima M, Ishida R, Shintomi K, Kowa Y (July 1971). "[Pharmacological properties of 6,6,9-trimethyl-9-azabicyclo (3,3,1)non-3 beta-yl-alpha, alpha-di(2-thienyl) glycolate hydrochloride monohydrate (PG-501), a new anti-parkinsonian agent]". Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica (in Japanese). 67 (4): 387–405. doi:10.1254/fpj.67.387. PMID 5000167.

[2] Kosaka K (1971). "パーキンソン病に対するPG-501の使用経験/The Beneficial Effect of PG-501 on Parkinsonism". Rinsho Yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics. 2 (3): 230–235. doi:10.3999/jscpt.2.230. Retrieved December 18, 2023.

[1]

[2]